Biopharmaceutical company Incyte Corporation (NASDAQ: INCY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on year to $1.67 billion. On the other hand, the company’s full-year revenue guidance of $5.20 billion at the midpoint came in 9.2% below analysts’ estimates. Its non-GAAP profit of $3.09 per share was 43.9% above analysts’ consensus estimates.
Is now the time to buy Incyte? Find out by accessing our full research report, it’s free.
Incyte (INCY) Q2 CY2026 Highlights:
- Revenue: $1.67 billion vs analyst estimates of $1.50 billion (37.7% year-on-year growth, 11.3% beat)
- Adjusted EPS: $3.09 vs analyst estimates of $2.15 (43.9% beat)
- The company lifted its revenue guidance for the full year to $5.20 billion at the midpoint from $4.86 billion, a 7% increase
- Operating Margin: 41.7%, down from 43.6% in the same quarter last year
- Market Capitalization: $23.75 billion
“Our second quarter was marked by broad-based sales growth, continued pipeline progress and strategic business development,” said Bill Meury, Chief Executive Officer, Incyte.
Company Overview
Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer, Incyte (NASDAQ: INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics for cancer and inflammatory diseases.
Revenue Growth
A company’s long-term sales performance can indicate its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Thankfully, Incyte’s 16.7% annualized revenue growth over the last five years was impressive. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis.
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Incyte’s annualized revenue growth of 22.8% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated. 
This quarter, Incyte reported wonderful year-on-year revenue growth of 37.7%, and its $1.67 billion of revenue exceeded Wall Street’s estimates by 11.3%.
Looking ahead, sell-side analysts expect revenue to remain flat over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will see some demand headwinds. At least the company is tracking well in other measures of financial health.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
Adjusted Operating Margin
Incyte has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average adjusted operating margin of 25.2%.
Analyzing the trend in its profitability, Incyte’s adjusted operating margin rose by 7.3 percentage points over the last five years, as its sales growth gave it operating leverage. This performance was mostly driven by its recent improvements as the company’s margin has increased by 27.4 percentage points on a two-year basis. These data points are very encouraging and show momentum is on its side.
In Q2, Incyte generated an adjusted operating margin profit margin of 44%, up 12.5 percentage points year on year. This increase was a welcome development and shows it was more efficient.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
Incyte’s EPS grew at 27.8% compounded annual growth rate over the last five years, higher than its 16.7% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.
Diving into the nuances of Incyte’s earnings can give us a better understanding of its performance. As we mentioned earlier, Incyte’s adjusted operating margin expanded by 7.3 percentage points over the last five years. On top of that, its share count shrank by 6.3%. These are positive signs for shareholders because improving profitability and share buybacks turbocharge EPS growth relative to revenue growth. 
In Q2, Incyte reported adjusted EPS of $3.09, up from $1.57 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Incyte’s full-year EPS to shrink by 69.2% from $8.96 to $2.76.
Key Takeaways from Incyte’s Q2 Results
It was good to see Incyte beat analysts’ EPS expectations this quarter. We were also excited its revenue outperformed Wall Street’s estimates by a wide margin. On the other hand, its full-year revenue guidance missed. Overall, this print had some key positives. The stock remained flat at $118.09 immediately after reporting.
Big picture, is Incyte a buy here and now? When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).
